Product Overview

Lamivir S 30 mg is a fixed dose combination antiretroviral tablet produced by Cipla Limited. Each tablet delivers lamivudine 30 mg together with stavudine 30 mg, two nucleoside reverse transcriptase inhibitors that work synergistically to suppress the replication of human immunodeficiency virus. The medication is packaged in a bottle containing 60 tablets and is also marketed in larger pack sizes of 120 and 180 tablets to accommodate patients who require extended treatment without frequent reordering. This product is specifically indicated for the management of HIV infection in adults and forms part of a comprehensive therapeutic strategy that includes regular laboratory monitoring, patient education, and supportive clinical care. The formulation is intended for oral administration and should be prescribed as part of a tailored antiretroviral regimen based on individual patient factors and treatment goals.

What is Lamivir S 30 mg

Lamivir S 30 mg belongs to the class of nucleoside reverse transcriptase inhibitors (NRTIs). The active components, lamivudine and stavudine, are chemically distinct but share a common mechanism of intracellular activation. Once inside cells, both drugs are phosphorylated to their respective triphosphate forms, which compete with the natural deoxynucleotides used by HIV reverse transcriptase. This competition leads to premature chain termination, preventing the virus from converting its RNA genome into DNA. The combination of two NRTIs in a single tablet provides a dual blockade of the viral polymerase, reducing the likelihood of resistance emergence compared with the use of a single agent. The oral tablet is designed for once‑daily dosing and is intended to be used as part of a broader antiretroviral cocktail that may include other classes such as protease inhibitors or integrase inhibitors, thereby enhancing overall virologic suppression.

Uses and Benefits

The primary therapeutic use of Lamivir S 30 mg is the suppression of HIV viral load in patients with confirmed infection. By dramatically reducing the amount of circulating virus, the regimen helps preserve CD4+ T‑cell counts and delays the onset of opportunistic infections and AIDS‑defining illnesses. Clinical trials have shown that combination regimens containing lamivudine and stavudine can achieve greater reductions in plasma HIV RNA than placebo, and they are often paired with other antiretroviral agents to create a potent suppressive backbone. In addition to virologic benefits, the fixed‑dose formulation improves patient adherence by simplifying the dosing schedule and eliminating the need for multiple separate pills. The availability of multiple pack sizes — 60, 120, and 180 tablets — allows clinicians to match supply with patient‑specific treatment duration, supporting long‑term disease control and reducing the burden of pharmacy visits.

How It Works

Lamivir S 30 mg exerts its antiviral activity through intracellular phosphorylation of both lamivudine and stavudine, producing active triphosphate metabolites that inhibit the HIV reverse transcriptase enzyme. These metabolites act as competitive substrates, causing early termination of the growing viral DNA strand and effectively halting the conversion of viral RNA into genetic material. Because the two agents share overlapping but distinct resistance profiles, their combined use creates a higher barrier to resistance development, making it more difficult for the virus to acquire mutations that render either component ineffective. This mechanistic synergy allows each drug to be administered at a lower individual dose, which can lessen the frequency of certain adverse events while maintaining robust antiviral potency. The overall effect is a durable reduction in viral replication when the regimen is adhered to consistently, especially when combined with regular laboratory monitoring and supportive care.

Dosage Guidelines

The standard adult dosage of Lamivir S 30 mg is one tablet taken orally once daily, with or without food. In patients with impaired renal function, dose adjustments may be required because both lamivudine and stavudine are primarily cleared by the kidneys. Clinicians typically order baseline renal function tests and may reduce the daily dose or extend the dosing interval in cases of moderate to severe renal impairment. If a dose is missed, the patient should not double the next dose; instead, they should resume the regular schedule as soon as possible. Ongoing monitoring of renal parameters and bone marrow function is recommended throughout therapy to detect any emerging toxicity early and to guide dose modifications if needed. Patients should be instructed to follow the prescribing clinician’s instructions precisely and to attend all scheduled laboratory appointments.

Side Effects

Like all antiretroviral medications, Lamivir S 30 mg can be associated with a range of adverse reactions. The most commonly reported side effects include gastrointestinal discomfort such as nausea, and peripheral neuropathy manifested by tingling, burning, or numbness in the hands and feet. Rare but serious hematologic complications, including anemia and neutropenia, may occur, particularly in individuals with pre‑existing bone marrow suppression. Elevations in liver enzymes have also been documented, necessitating periodic liver function testing. Additional adverse events reported in clinical studies include insomnia, peripheral edema, and metabolic disturbances such as increased lactate levels. Patients should be advised to report any new or worsening symptoms promptly, and healthcare providers should consider dose adjustments or alternative therapies when clinically appropriate. For a comprehensive list of side effects, refer to reputable drug information sources such as Drugs.com.

Warnings and Precautions

Lamivir S 30 mg should be prescribed with caution in patients who have a history of hepatic disease, severe renal dysfunction, or peripheral neuropathy. The medication is not recommended for use during pregnancy unless the potential benefit to the mother outweighs any possible risk to the fetus, and breastfeeding is generally discouraged because the active substances can be excreted in milk. Concomitant use with other antiretroviral agents that share metabolic pathways may increase the risk of toxicity, so a thorough drug‑interaction review is essential before initiating therapy. Routine laboratory monitoring — including complete blood count, serum amylase, and renal function tests — should be performed at regular intervals to identify early signs of hematologic or hepatic toxicity. Special consideration is advised for pediatric patients, in whom dosing must be weight‑based and renal clearance assessed. Pregnant women should discuss potential risks with their healthcare provider, and all patients should be counseled about the importance of adherence to reduce the risk of viral resistance. Additional safety information can be accessed through the National Institutes of Health resource on HIV treatment National Institutes of Health.

Frequently Asked Questions

1. What are the active ingredients in Lamivir S 30 mg
2. Answer The tablet contains lamivudine 30 mg and stavudine 30 mg, both classified as nucleoside reverse transcriptase inhibitors used together to suppress HIV replication.
3. How long does delivery take after ordering
4. Answer Delivery typically occurs within six to fifteen days depending on the shipping destination and carrier performance.
5. Can Lamivir S 30 mg be taken with other medications
6. Answer It should be used only under medical supervision and may interact with drugs that affect renal function or other antiretrovirals, so a healthcare provider should review all concomitant therapies.
7. Is the medication safe during pregnancy
8. Answer The safety profile in pregnancy is not fully established; therefore, it should only be used if the clinician determines that the benefits outweigh any potential risks to the fetus.

Related Products

• Ciplox 750mg (Ciprofloxacin)
• Diclofenac SR 100 mg
• Reactin 50 mg (Diclofenac)
• Cromal Forte Eye Drop (Sodium Cromoglycate)
• Alendronic Acid 35 mg (Generic)
• Rizact 5 mg (Rizatriptan)
• Flunarizine 5 mg (Generic)
• Warf 1 mg (Warfarin)
• Warf 2 mg (Warfarin)
• Warf 3 mg (Warfarin)
• Mucinac 200 mg (Acetylcysteine)
• Temozolomide 20 mg (Generic)